Overview of Dr. Lammers
Dr. Philip Lammers is an oncologist in Memphis, TN and is affiliated with Baptist Memorial Hospital-Tipton. He received his medical degree from Indiana University School of Medicine and has been in practice 11 years. He is one of 18 doctors at Baptist Memorial Hospital-Tipton who specialize in Oncology. He has more than 30 publications and over 500 citings.
Office
80 Humphreys Center
Suite 330
Memphis, TN 38120
Education & Training
Vanderbilt University Medical CenterFellowship, Hematology and Medical Oncology, 2009 - 2012
Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 2006 - 2009
Indiana University School of MedicineClass of 2006
Certifications & Licensure
MS State Medical License 2019 - 2025
TN State Medical License 2009 - 2025- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer Start of enrollment: 2015 Jul 26
- Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
- Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
- Join now to see all
Publications & Presentations
PubMed
- 24 citationsParticipant choices for return of genomic results in the eMERGE Network.Christin Hoell, Julia Wynn, Luke V. Rasmussen, Keith Marsolo, Sharon Aufox
Genetics in Medicine. 2020-07-16 - 26 citationsTrilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy-induced myelosuppression in patients with small cell lung cancer:...Renata Ferrarotto, Ian Anderson, Balazs Medgyasszay, Maria Rosario García-Campelo, William Jeffery Edenfield
Cancer Medicine. 2021-09-01 - 45 citationsBispecific antibodies in the treatment of hematologic malignanciesJohannes Duell, Philip E. Lammers, Ivana Djuretic, Allison Given Chunyk, Shilpa Alekar
Clinical Pharmacology and Therapeutics. 2019-03-29
Press Mentions
- Memphis People in Business: March 25, 2021March 25th, 2021
FDA Approves Herceptin Biosimilar Ontruzant for HER2-Positive Breast CancerJuly 24th, 2019
Cancer Disparities Grant with Meharry, TSU Gains RenewalOctober 20th, 2016- Join now to see all
Committees
- NCORP national representative, SWOG Breast Cancer Committee 2018 - Present
Professional Memberships
- Member
- International Association for the Study of Lung CancerMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
